Mystery Solved? GenSight’s Gene Therapy Does Move Between Eyes
Company hopes to file in Europe next year
Company boosted by animal study which helps answer riddle of improvement in untreated eye.
You may also be interested in...
Phase III success at 96 weeks sets up GenSight blindness therapy for EU filing, but puzzle of placebo arm benefits remain
Already partnering with AZ and Boehringer Ingelheim in liver targets, the UK biotech sees potential to hit ‘undruggable’ CNS targets as well.
Key cancer asset is still looking for a Phase III validation after failing to outperform Keytruda in challenging frontline NSCLC setting.